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Abstract
Background: Testes-specific protease 50 (TSP50) is normally expressed in testes and abnormally expressed in breast cancer,
but whether TSP50 is expressed in colorectal carcinoma (CRC) and its clinical significance is unclear. We aimed to detect
TSP50 expression in CRC, correlate it with clinicopathological factors, and assess its potential diagnostic and prognostic
value.
Methodology/Principal Findings: TSP50 mRNAs and proteins were detected in 7 CRC cell lines and 8 CRC specimens via RT-
PCR and Western blot analysis. Immunohistochemical analysis of TSP50, p53 and carcinoembryonic antigen (CEA) with
tissue microarrays composed of 95 CRCs, 20 colorectal adenomas and 20 normal colorectal tissues were carried out and
correlated with clinicopathological characteristics and disease-specific survival for CRC patients. There was no significant
correlation between the expression levels of TSP50 and p53 (P=0.751) or CEA (P=0.663). Abundant expression of TSP50
protein was found in CRCs (68.4%) while it was poorly expressed in colorectal adenomas and normal tissues (P,0.0001).
Thus, CRCs can be distinguished from them with high specificity (92.5%) and positive predictive value (PPV, 95.6%). The
survival of CRC patients with high TSP50 expression was significantly shorter than that of the patients with low TSP50
expression (P=0.010), specifically in patients who had early-stage tumors (stage I and II; P=0.004). Multivariate Cox
regression analysis indicated that high TSP50 expression was a statistically significant independent risk factor (hazard ratio
=2.205, 95% CI=1.214–4.004, P=0.009).
Conclusion: Our data demonstrate that TSP50 is a potential effective indicator of poor survival for CRC patients, especially
for those with early-stage tumors.
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Introduction
The testes-specific protease 50 (TSP50) gene was discovered
from a human testes cDNA library on a hypomethylated DNA
fragment isolated from human breast cancer cells via the
methylation sensitive-representational difference analysis tech-
nique [1]. It encodes a threonine protease which is homologous
to serine proteases, but its crucial catalytic triad has a substitution
of threonine at the serine residue site [2]. TSP50 is normally and
specifically expressed in the spermatocytes of testes, abnormally
activated and expressed in most (more than 90%) breast cancer
biopsies, and negatively regulated by the p53 gene, which can in
turn promote tumorigenesis [2–4]. Further, previous investigations
found that basic fibroblast growth factor (bFGF) could downreg-
ulate TSP50 expression via the ERK/Sp1 pathway due to TSP50
gene promoter containing Sp1 binding site [5,6]. Most impor-
tantly, recent studies reported that knockdown of TSP50 gene
expression could inhibit cell proliferation, colony formation and
migration, induce cell apoptosis, and enhance cell sensitivity to
doxorubicin [7], and the underlying molecular mechanisms might
be related to activation of the NF-kB signaling pathway [8]. These
results imply that the TSP50 gene should be an oncogene, and the
TSP50 protein might be a biomarker for human breast cancer.
Based on the information above, TSP50 is considered as a cancer/
testis antigen (CTA) [3,9]. Many CTAs, such as MAGEA1, NY-
ESO-1, SYCP1, BRDT, HOM-TES-85, NFX2 and SSX-1, are
expressed in various human cancers [10–17]. However, to our
knowledge, there is no report that TSP50 has been detected in
other human malignancies except breast cancer.
Previous studies have demonstrated that the TSP50 gene
promoter’s DNA methylation status most likely control the gene
expression in different types of tissues [18]. DNA methylation is
associated with TSP50 gene silencing in many normal tissues such
as breast, lung and kidney. Conversely, DNA demethylation is
associated with elevated levels of TSP50 gene expression in the
testes and breast cancer [1,18]. Moreover, global hypomethylation
is common and prominent in colorectal carcinoma (CRC) as
compared to normal colorectal tissue [19–21], and some other
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22203CTAs have already been detected in CRC [22–24]. Therefore, we
speculated that TSP50 could be expressed in CRC.
To date, the expression state of TSP50 gene in CRC and its
relationship with clinicopathological/prognostic significance is
unknown. We aimed to analyze the expression status of TSP50 in
CRCs compared with colorectal adenomas and normal tissues,
determine its relationship with clinicopathological parameters, and
investigate its prognostic value for CRC patients based on tumor
stage (earlyand advancedstage).Inaddition,p53 proteinexpression
was examined to investigate its correlation with TSP50 expression
in CRCs, and the prognostic significance of carcinoembryonic
antigen (CEA), a well established prognostic factor for CRC, was
analyzed to verify the reliability of this cohort of CRC patients. We
found that TSP50 could be a very useful predictor for unfavorable
prognosis in patients with CRC.
Results
Detection of TSP50 expression in the CRC cell lines and
tissues
Aberrant expression of TSP50 was detected in all the 7 CRC cell
lines by RT-PCR and Western blot analysis (Figure 1A and B).
Total RNA and protein from the breast carcinoma cell line MDA-
MB-231 served as positive controls, and b-actin served as internal
control. TSP50 was expressed in all the 8 CRC samples, and not or
weakly expressed in the adjacent normal colorectal tissues
(Figure 1C). TSP50 expression levels were obviously higher in most
CRC samples than those in the adjacent normal colorectal tissues.
Immunohistochemical analysis of TSP50 expression in
colorectal normal tissues, adenomas and CRCs
The breast carcinoma sections which were incubated with PBS or
antibodies to TSP50 served as negative control (Figure 2A) or
positive control (Figure 2B). TSP50 expression wasvariable:grade2
and 1+ in the colorectal normal epithelium (Figure 2C and D); grade
2,1 + and 2+ in colorectal adenomas (Figure 2E–G); grade 2,1 +,
2+ and 3+ in CRCs (Figure 2H–K). TSP50 proteins were observed
predominantly in the cytoplasm,but exhibited inthe membrane and
cytoplasm of some CRC samples (Figure 2J and K, arrows). TSP50
expression levels in CRCs were significantly higher than those in
colorectal normal tissues or adenomas (P,0.0001; Table 1).
Relationship between TSP50 expression and p53 or CEA
expression
Expression of p53 protein was observed in the nucleus of
carcinoma cells (Figure 3A and B), and the levels were variable:
grade 2 in 47 (49.5%) cases, grade 1+ in 15 (15.8%) cases, grade
2+ in 17 (17.9%) cases, and grade 3+ in 16 (16.8%) cases of 95
CRCs (Table 1). CEA was expressed in the cytoplasm and/or
membrane of carcinoma cells (Figure 3C and D), and its
expression was variable: grade 2 in 14 (14.7%) cases, grade 1+
in 26 (27.4%) cases, grade 2+ in 40 (42.1%) cases, and grade 3+ in
15 (15.8%) cases (Table 1). There was no significant correlation
between TSP50 and p53 or CEA expression (Table 1).
Relationship between clinicopathologic features and
TSP50, p53 or CEA expression
There was no significant association between TSP50 expression
status in CRCs and all the clinicopathologic features including age,
sex, depth of invasion, lymph node metastasis, and tumor location,
size, stage and grade (Table 2). p53 overexpression was signi-
ficantly associated with tumor location (P=0.033), and CEA
expression was negatively correlated with tumor grade (P=0.020),
but both were not related with other clinicopathologic character-
istics analyzed (Table 2).
Evaluation of TSP50 as potential diagnostic marker for
CRC
Receiver operating characteristic (ROC) analysis was used to
determine the potential of TSP50 overexpression to distinguish
CRCs from colorectal adenomas and normal tissues (Figure 4).
The value of area-under-the-curve (AUC) was 0.812 (95%
confidence interval (CI)=0.741–0.883, P,0.001). Based on the
best Youden index (the maximum value of [sensitivity + specificity
– 1]) for TSP50, a cutoff score $4( 2 +) was as positive criterion for
statistical analysis of TSP50 immunostaining. The sensitivity,
specificity, positive predictive value (PPV), negative predictive
Figure 1. Expression of TSP50 in CRC cell lines and tissue specimens. (A) RT-PCR of TSP50 expression in the 7 CRC cell lines; (B) Western blot
analysis of TSP50 expression in the 7 CRC cell lines; (C) Western blot analysis of TSP50 expression in 8 CRC specimens (T) and adjacent normal
colorectal specimens (N) paired from the same patient. Total RNA and protein from the breast cancer cell line MDA-MB-231 served as the positive
controls. b-actin served as internal control.
doi:10.1371/journal.pone.0022203.g001
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55.2% and 60.9%, respectively (Table 3).
Evaluation of TSP50 as potential prognostic marker for
CRC
At the last follow-up, 60 of 95 patients (63.2%) had died from
CRC, 29 of 95 patients (30.5%) remained alive, and 6 of 95
patients (6.3%) had died from other causes or lost touch.
Univariate Kaplan-Meier survival analysis of the complete CRC
patients (n=95) based on TSP50 expression demonstrated that the
disease-specific survival period was significantly shorter for patients
with high TSP50 expression than for patients with low TSP50
expression (log-rank P=0.010; Figure 5A). This result was similar
with survival analysis based on CEA expression (log-rank
P=0.013; Figure 5B). Survival analyses, in early-stage (stage I
and II) and advanced-stage (stage III and IV) group of CRC
patients respectively, demonstrated that TSP50 overexpression
was associated with shortened disease-specific survival for patients
with early-stage CRC (log-rank P=0.004; Figure 5C), but not for
patients with advanced stage (log-rank P=0.274; Figure 5D).
Univariate Kaplan-Meier survival analysis based on clinicopath-
ologic features showed that lymph node metastasis (log-rank
P,0.0001), tumor stage (log-rank P,0.0001) and tumor grade
(log-rank P=0.022) were statistically significant risk factors
affecting the disease-specific survival of CRC patients, except
other clinicopathologic parameters (age, sex, tumor location,
tumor size and depth of invasion; Table 2). In addition, high CEA
expression was correlated with shorter survival for CRC patients
(log-rank P=0.013; Figure 5B), but a high or low expression of
p53 was not related to the survival of CRC patients (data not
show).
Cox regression analysis was carried out to evaluate the potential
prognostic significance of TSP50 and CEA expression on CRC-
specific survival in comparison with the clinicopathologic param-
eters. The backward stepwise multivariate regression analysis
demonstrated that TSP50 expression, CEA expression and tumor
stage were statistically significant independent prognostic indica-
tors for CRC (Table 4).
Discussion
This is the first study, to our knowledge, to report TSP50
expression in primary CRCs and evaluate its diagnostic and
Figure 2. Immunohistochemical analysis of TSP50 in colorectal tissue microarrays. (A) The breast carcinoma section that was incubated
with PBS served as negative control; (B) The breast carcinoma section that was incubated with antibodies to TSP50 served as positive control; (C–D) A
sample of TSP50 expression levels in colorectal normal tissues: 2 in C and 1+ in D; (E–G) A sample of TSP50 expression levels in colorectal adenomas:
2 in E, 1+ in F and 2+ in G; (H–K) A sample of TSP50 expression levels in CRCs: 2 in H, 1+ in I, 2+ in J and 3+ in K; some CRC samples exhibited
membrane staining (arrows in J and K). Original magnification, 6200 in A–K and 6400 in inset.
doi:10.1371/journal.pone.0022203.g002
Table 1. Relationship between TSP50 expression and type of
colorectal tissues or expression status of p53 or CEA.
TSP50 expression (%) P
2 + ++ +++
Tissue type
Normal 8 (40.0) 12 (60.0) 0 (0.0) 0 (0.0) ,0.0001
a
Adenoma 4 (20.0) 13 (65.0) 3 (15.0) 0 (0.0)
CRC 10 (10.5) 20 (21.1) 57 (60.0) 8 (8.4)
p53 expression
2 5 (5.2) 8 (8.4) 30 (31.6) 4 (4.2) 0.751
b
+ 2 (2.1) 2 (2.1) 10 (10.5) 1 (1.1)
++ 1 (1.1) 7 (7.4) 8 (8.4) 1 (1.1)
+++ 2 (2.1) 3 (3.2) 8 (8.4) 3 (3.2)
CEA expression
2 2 (2.1) 3 (3.2) 9 (9.5) 0 (0.0) 0.663
b
+ 2 (2.1) 8 (8.4) 15 (15.8) 1 (1.1)
++ 3 (3.2) 7 (7.4) 23 (24.2) 7 (7.4)
+++ 3 (3.2) 2 (2.1) 9 (9.5) 1 (1.1)
a, Kruskal Wallis Test; b, Spearman’s rho.
TSP50, testes-specific protease 50; CRC, colorectal carcinoma; CEA,
carcinoembryonic antigen.
doi:10.1371/journal.pone.0022203.t001
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abnormally highly expressed in CRCs in comparison with
colorectal adenomas and normal tissues; (b) TSP50 expression is
unrelated to p53 expression in CRC; (c) TSP50 overexpression
distinguishes CRCs from colorectal adenomas and normal tissues
with high specificity and PPV; and (d) high TSP50 expression in
CRC is a novel independent factor for unfavorable prognosis.
Previous studies indicate that TSP50 is normally and specifically
expressed in the spermatocytes of testes, and abnormally highly
expressed in breast cancer cells and tissues, and it locates in the
endoplasmic reticulum and the cytoplasm membrane [1,2,4]. In
the present study, aberrant expression of TSP50 was found in the
7 CRC cell lines (Figure 1A and B), and its level was elevated in
CRC compared with adjacent normal tissue (Figure1C). These
results were confirmed by immunohistochemical analysis of CRCs,
colorectal adenomas and normal tissues (Table 1). Similar to the
earlier studies, TSP50 expression was observed predominantly in
the cytoplasm of CRCs, and some CRC samples demonstrated
membrane staining along with cytoplasmic localization (Figure 2J
and K). Although an earlier investigation reported that TSP50 was
not expressed in normal colon tissues by Northern blot analysis
[1], weak expression of TSP50 in some normal colorectal tissues
were observed by Western blot and immunochemical analysis in
our study (Figure 1C and 2D). A possible explanation for this
discrepancy is that previous investigation did not detect those
normal colon tissues which weakly expressed TSP50. Interestingly,
many other CTAs show low-level expression in a limited number
of somatic tissues [16,25].
We did not find any relationship between TSP50 expression
and p53 expression by immunohistochemical analysis (Table 1).
Antibodies used for immunohistochemistry can detect both the
wild-type and the mutated p53 protein, and TSP50 expression is
significantly higher in breast cancer cells in which p53 gene is
mutated [4], so TSP50 expression might be correlated with the
status of p53 gene but not with the accumulated quantity of p53
protein in CRC. In this study, we found p53 expression was
associated with tumor location as other authors did [26]. In
contrast, some studies did not find any relationship to clinico-
pathological features [27–30], and others found a close relation to
lymph node metastasis, invasion depth, distant metastasis or Dukes
stage [31–34]. We did not find a correlation of p53 expression and
prognosis, which is consistent with some previous studies [30,35–
39]. However, some investigations reported p53 expression had a
better survival [26,28,40], and others reported poor prognosis in
patients with p53-positive carcinomas [29,34,41–43]. Thus, the
relationship between p53 expression and survival is still contro-
versial. The discrepancies may result from different techniques
used in these studies, such as different antibodies, scoring systems,
cutoff-values and study populations. It has been found that p53
gene encodes for at least ten different isoforms resulted from
differential promoter utilization and alternative splicing [44,45].
Each p53 isoform has different subcellular localisation and dis-
tinct biological activity, and some p53 isoforms were abnormally
expressed in several tumor types [46]. Thus, it is proposed that
some specific isoforms might be related to cancer prognosis.
However, so far as we know, there is no report about the pro-
gnostic value of any specific isoform in CRC. Further investiga-
tions along this direction would open new perspectives for p53
studies. In addition, p53 mutations, especially in exon 5 to 8 or
codon 72, predicting poor survival in CRC patients are found by
many studies [47–53], but it is still far from conclusion. Besides
some contradictory results [54–56], the European Group of
Tumor Markers (EGTM) and the American Society of Clinical
Oncology (ASCO) did not recommend p53 mutation detection for
screening, diagnosis, staging, surveillance, determining prognosis
or monitoring treatment of patients with CRC [57,58]. On the
Figure 3. Representative immunohistochemical staining of p53 and CEA in CRCs. (A) Low expression of p53; (B) High expression of p53 in
the nucleus of carcinoma cells; (C) Low expression of CEA; (D) High expression of CEA in the cytoplasm and membrane of carcinoma cells. Original
magnification, 6200.
doi:10.1371/journal.pone.0022203.g003
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cancer prognosis is much more complex than hitherto appreciat-
ed. It requires an integrated and complex analysis of p53
expression level, isoform type and gene mutation.
The significant increase of TSP50 overexpression observed in
CRCs (65 of 95 cases, 68.4%) as compared to colorectal adenomas
and normal tissues (3 of 40 cases, 8%) is an important finding of
our study, but there is no obvious correlation between TSP50
expression in CRCs and the clinicopathologic features (Table 2).
In the further study of TSP50 diagnostic value for CRC, the ROC
curve and Youden index were used for identifying the cutoff point
at which optimal sensitivity and specificity were achieved, and the
AUC showed the discriminatory power for TSP50 in CRCs. The
high specificity and PPV but relatively low sensitivity and NPV
indicate that TSP50 could accurately distinguish CRCs from
colorectal adenomas and normal tissues but be not suitable for
early screening of CRC. In addition, the value of Youden index
and AUC demonstrate that this diagnostic method can be with
relatively high validity and accuracy. TSP50 is hence an attractive
and potential target for diagnosis and therapy.
In our study, survival analysis based on tumor stage (early and
advanced stage) indicates that TSP50 is a prognostic factor of
reduced survival in CRC patients, especially in those with early-
stage tumors (stage I and II; Figure 5A and C). A statistically
significant survival difference between high and low TSP50
expression was not observed for CRC patients in advanced stage
(stage III and IV; Figure 5D), but studies with larger samples are
needed to assess the prognostic importance of TSP50 expression in
patients with CRC of this stage. Further, the multivariate Cox
regression analysis demonstrated that increased expression of
TSP50 is an independent indicator of unfavorable prognosis for
patients with CRC (Table 4). Similarly, for a given cancer type,
higher expression of some other CTAs is often correlated with
worse outcome, such as MAGE-A3 for pancreatic cancer [59],
MAGE-C2 for hepatocellular carcinoma [60], and NY-ESO-1 for
malignant melanoma [61]. A recent study demonstrates that high
Table 2. Association between clinicopathologic features and survival or expression level of TSP50, p53 or CEA in CRCs.
Variables Cases
Survival P
(log-rank) TSP50 expression (%) p53 expression (%) CEA expression (%)
Low High P (x
2) Low High P (x
2) Low High P (x
2)
Total number of patients 95 30 (31.6) 65 (68.4) 62 (65.3) 33 (34.7) 40 (42.1) 55 (57.9)
Age group, y
#56 47 0.727 19 (40.4) 28 (59.6) 0.066 32 (68.1) 15 (31.9) 0.568 23 (48.9) 24 (51.1) 0.182
.56 48 11 (22.9) 37 (77.1) 30 (62.5) 18 (37.5) 17 (35.4) 31 (64.6)
Sex
Women 40 0.301 13 (32.5) 27 (67.5) 0.869 25 (62.5) 15 (37.5) 0.630 17 (42.5) 23 (57.5) 0.947
Men 55 17 (30.9) 38 (69.1) 37 (67.3) 18 (32.7) 23 (41.8) 32 (58.2)
Tumor location
Colon 40 0.450 9 (22.5) 31 (77.5) 0.104 31 (77.5) 9 (22.5) 0.033 16 (40.0) 24 (60.0) 0.723
Rectum 55 21 (38.2) 34 (61.8) 31 (56.4) 24 (43.6) 24 (43.6) 31 (56.4)
Tumor size, cm
#4 50 0.602 16 (32.0) 34 (68.0) 0.926 29 (58.0) 21 (42.0) 0.117 21 (42.0) 29 (58.0) 0.983
.4 45 14 (31.1) 31 (68.9) 33 (73.3) 12 (26.7) 19 (42.2) 26 (57.8)
Depth of invasion
T2 20 0.080 4 (20.0) 16 (80.0) 0.174 15 (75.0) 5 (25.0) 0.566 9 (45.0) 11 (55.0) 0.305
T3 44 18 (40.9) 26 (59.1) 27(61.4) 17 (38.6) 15 (34.1) 29 (65.9)
T4 31 8 (25.8) 23 (74.2) 20 (64.5) 11 (35.5) 16 (51.6) 15 (48.4)
Lymph node metastasis
N0 55 ,0.0001 18 (32.7) 37 (67.3) 0.862* 35 (63.6) 20 (36.4) 0.569* 27 (49.1) 28 (50.9) 0.157
N1 26 7 (26.9) 19 (73.1) 19 (73.1) 7 (26.9) 10 (38.5) 16 (61.5)
N2 14 5 (35.7) 9 (64.3) 8 (57.1) 6 (42.9) 3 (21.4) 11 (78.6)
Tumor stage
I1 4 ,0.0001 3 (21.4) 11 (78.6) 0.798* 12 (85.7) 2 (14.3) 0.238* 6 (42.9) 8 (57.1) 0.413*
II 41 15 (36.6) 26 (63.4) 23 (56.1) 18 (43.9) 21 (51.2) 20 (48.8)
III 29 9 (31.0) 20 (69.0) 20 (69.0) 9 (31.0) 10 (34.5) 19 (65.5)
IV 11 3 (27.2) 8 (72.8) 7 (63.6) 4 (36.4) 3 (27.3) 8 (72.7)
Tumor grade
Low 75 0.022 22 (29.3) 53 (71.7) 0.362 47 (62.7) 28 (37.3) 0.303 27 (36.0) 48 (64.0) 0.020
High 20 8 (40.0) 12 (60.0) 15 (75.0) 5 (25.0) 13 (65.0) 7 (35.0)
Median values were used as cut-off points for definition of subgroups (age group and tumor size).
*Fisher’s Exact Test.
TSP50, testes-specific protease 50; CRC, colorectal carcinoma; CEA, carcinoembryonic antigen.
doi:10.1371/journal.pone.0022203.t002
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proliferation, colony formation and migration [7], which may
preliminarily explain the reason why TSP50 predict poor
prognosis.
CEA is a widely accepted prognostic factor for CRC
[57,58,62,63]. Since the sample size was small, the CEA
prognostic significance was tested in this cohort of CRC patients
to verify their reliability. We examined CEA expression in tumor
tissues (t-CEA) by immunohistochemical staining instead of
preoperative CEA in serum (s-CEA), for the following two reasons:
(a) for most patients in our study preoperative s-CEA was not
detected; and (b) the prognosis value of t-CEA may be stronger
than that of s-CEA in CRC due to the fact that level of s-CEA is
affected by many factors, such as liver diseases, bowel obstruction
and smoking, which could influence CEA production, release and
metabolism [64]. Consistent with the earlier study, we found that
t-CEA was also an independent predictor in this cohort of CRCs
(Figure 5B; Table 4), and this result reveals that the cases selected
are credible. In addition, it was found that well and moderately
differentiated CRCs expressed increased t-CEA compared with
poorly differentiated and undifferentiated tumors (P=0.020). This
finding is compatible with a report that s-CEA tends to be elevated
in patients with well differentiated CRCs in comparison with
poorly differentiated tumors [65].
In conclusion, we firstly report that TSP50 is abnormally and
strongly expressed in CRCs, and it is a potential effective predictor
for poor prognosis in CRC patients, especially for those at early
stage. Though CRC is diagnosed on the basis of the results of
colonoscopy or sigmoidoscopy with tumor biopsy [66], TSP50
might play a role on auxiliary diagnosis and become an attractive
novel target for molecular imaging and therapy due to its high
specificity and PPV for CRC. Determination of the TSP50
expression levels should help in identifying CRC patients with
high risk, and that would be useful in the selection of patients for
appropriate therapies. For example, the CRC patients with high
TSP50 expression should accept a more aggressive treatment
regimen and be followed-up carefully. Our findings remain to be
validated in larger retrospective and prospective studies. More
detailed elucidations of the function of TSP50 also require
performing further molecular studies.
Materials and Methods
Ethic Statement
This study complied with the Helsinki Declaration and was
approved by the Ethical Committee of Southwest Hospital of
Third Military Medical University (Chongqing, China; Figure S1).
Through the surgery informed consent form, our patients had
already been informed that the resected specimens were kept by
our hospital and might be used for scientific research but did not
relate to patient’s privacy. We further obtained the verbal consent
of patients or their relatives by telephone during the follow-up.
Cell lines and cell culture
CRC cell lines SW480, SW620, LoVo, HT-29, HCT 116, LS
174T and Caco-2 were obtained from the American Type Culture
Collection. The breast carcinoma cell line MDA-MB-231 (a gift
from Dr. Zhenning Tang, Breast Disease Center, Southwest
Hospital, Third Military Medical University) was used as a postive
control. The cells were cultured at 37uC in a humidified
atmosphere of 95% air, 5% CO2 using DMEM (High Glucose)
with 10% fetal bovine serum (Hyclone, Thermo Fisher Scientific,
Waltham, MA, USA).
RT-PCR
Total RNA was isolated from the cell lines by RNAiso Plus
(TaKaRa Bio, Shiga, Japan). The first-strand cDNA was
synthesized by ReverTra Ace -a- kit (TOYOBO, Osaka, Japan)
following the manufacturer’s instruction. The sense and antisense
primers of TSP50 were 59-CGCTCCTGTGGCTTTTCCTAC-
39 and GGAGGCGGTCTGCGTCAT-59. The predicted size
was 234 bp. b-actin was used as the internal control, the sense and
antisense primers of which were 59-ACCCCGTGCTGCTGA-
CCGAG -39 and 59-TCCCGGCCAGCCAGGTCCA -39. The
Figure 4. Receiver operating characteristic (ROC) curve of
TSP50 in normal and adenoma vs CRC. Y-axis of the plot shows
true-positive fraction (sensitivity) and X-axis shows false positive
fraction (1-specificity). The arrow shows the part of the curve
corresponding to the optimal cut-off values.
doi:10.1371/journal.pone.0022203.g004
Table 3. Biomarker analysis of TSP50 in CRC.
Variables Sensitivity Specificity PPV NPV Youden index AUC (95% CI)
Normal and adenoma vs.CRC 68.4% 92.5% 95.6% 55.2% 62.0% 0.812 (0.741–0.883)
TSP50, testes-specific protease 50; CRC, colorectal carcinoma; PPV, positive predictive values; NPV, negative predictive values; Youden index was calculated as the
maximum (sensitivity + specificity - 1); AUC, area under the curve; CI, confidence interval.
doi:10.1371/journal.pone.0022203.t003
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comprised of cDNA derived from 200 ng of RNA, 2.5((l of 10(Ex
Taq Buffer, 2((l of 25 mM MgCl2, 2((l of 10 mM deoxynucleotide
triphosphates, 0.625 units of Ex Taq DNA polymerase (TaKaRa
Bio), 10 pmol of sense and antisense primers from TSP50 or b-
actin in a total volume of 25((l. PCR parameters were as follows:
Figure 5. Kaplan-Meier survival curves illustrating the significance of TSP50 expression in comparison with CEA expression in CRC.
(A) Overall, CRC patients with high TSP50 expression had shorter CRC-specific survival than those with low TSP50 expression (log-rank P=0.010); (B)
High CEA expression was associated significantly with poor CRC-specific survival relative to low CEA expression (log-rank P=0.013); (C) In early-stage
CRC (stage I and II), patients with high TSP50 expression had a significantly reduced CRC-specific survival relative to those with low expression (log-
rank P=0.004); (D) There was no significant difference between low and high expression of TSP50 in patients with advanced-stage CRC (stage III and
IV; log-rank P=0.274).
doi:10.1371/journal.pone.0022203.g005
Table 4. Backward stepwise multivariate regression analysis of prognostic factors.
Prognostic variables Indicator of poor prognosis HR (95% CI) P-Value
TSP50 expression: Low vs. high High expression 2.205 (1.214–4.004) 0.009
CEA expression: Low vs. high High expression 1.813 (1.062–3.096) 0.029
Tumor stage:
I vs II II 1.988 (0.796–4.961) 0.141
I vs III III 3.430 (1.380–8.526) 0.008
I vs IV IV 18.781 (6.316–55.846) ,0.0001
Age, depth of invasion, lymph node metastasis, tumor size and tumor grade were excluded from the model because of P.0.05.
TSP50, testes-specific protease 50; CRC, colorectal carcinoma; CEA, carcinoembryonic antigen; HR, hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0022203.t004
TSP50: A Novel Prognostic Biomarker
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22203initial denaturation at 94(C for 5 min, followed by 30 cycles
(denaturation at 94(C for 30 s, annealing at 55(C for 30 s, and
extension at 72(C for 30 s) and final extension at 72(C for 5 min.
The PCR products were separated on a 2% agarose gel. The
experiments were done three times.
Western blot analysis
Total protein in the cell lines and tissues (8 pairs of CRC and
adjacent normal colorectal specimens from 8 patients randomly
selected) was released by Ready Prep Protein Extraction Kit (Bio-
Rad, Hercules, CA, USA). Protein concentration in each lysate
was quantified using the bicinchoninic acid protein assay reagent
kit (Pierce, Rockford, IL, USA). The total protein was subjected
to 10% SDS/PAGE, and the resolved proteins were transferred
electrophoretically to PVDF membranes (Millipore, Bedford,
MA, USA). The membranes were blocked for 2 h with 5% non-
fat milk in TBS buffer containing 0.05% Tween-20 (TBST) at
4uC, and then incubated with rabbit polyclonal antibodies to
TSP50 (1:500; Covalab, Cambridge, UK) and mouse monoclonal
antibodies to b-actin (1:400; Santa Cruz Biotechnology, CA,
USA) respectively overnight at 4uC. After washing in TBST, the
membranes were incubated with their respective secondary
antibodies for 1 h, then incubated with SuperSignal West Femto
Maximum Sensitivity Substrate (Pierce) for 1 min and imaged
using a Gel Doc XR system (Bio-Rad). The experiments were
done three times.
Case selection and demographics
Ninety-five patients with primary CRC (mean age, 55 years old;
age range, 23–82 years old) who underwent surgical resection at
Southwest Hospital between 1997 and 2003 were identified.
Patients who had a personal history of CRC or other malignancies
were excluded. To control for treatment bias, the patients with
CRC who were included were those who had undergone surgery
and not received radiation therapy or presurgical chemotherapy
across all tumor stages (stages I–IV). Postsurgical chemotherapies
were performed depending on the severity of the disease and
according to the National Comprehensive Cancer Network
(NCCN) guidelines. Besides, 20 normal colorectal tissues from
20 body donors without intestinal disease, 20 colorectal adenomas
from 20 patients and 3 breast cancer tissues from 3 patients before
any anticancer therapy were collected. All the tissue blocks were
formalin-fixed and paraffin-embedded (FFPE).
Patient demographics, along with clinical and follow-up
information, were retrieved retrospectively from medical records
and pathology reports. Through telephone and mail contacts, we
ascertained outcome information directly from patients or
relatives. Demographic data were collected, including patient
age at diagnosis, sex, date of surgery, date of last follow-up (if alive)
and date of death.
Pathologic characteristics
Three pathologists (X.C.Y., G.J.D. and Q.L.W.) individually
reviewed the surgical pathology reports and slides stained with
hematoxylin and eosin for the degree of CRC histologic
differentiation. The CRC tissues were regarded as well
differentiated, moderately differentiated, poorly differentiated or
undifferentiated according to the World Health Organization
(WHO) guidelines. Reevaluation was necessary to reach a
consensus when there was a disagreement among the three
pathologists. The examined CRC cases were divided into two
groups: the low-grade group, composed of well differentiated and
moderately differentiated tumors, and the high-grade group,
composed of poorly differentiated and undifferentiated tumors
[67]. Pathologic staging was performed according to Union for
International Cancer Control (UICC) criteria 7
th Edition. The
anatomic locations of the CRC lesions were classified into two
groups: the colon and the rectum. Three-dimensional tumor size
was measured, and the largest tumor dimension was used for
statistical analysis.
Tissue microarrays and immunohistochemical staining
Ninety-five CRCs, 20 colorectal adenomas and 20 normal
colorectal tissues were made into tissue microarrays using the
t i s s u ea r r a y e rT M A - 1( B e e c h e rI n s t r u m e n t s ,W A ,U S A )a s
described previously [68]. The breast cancer FFPE blocks were
cut into 4-mm-thick sections. Immunohistochemistry was
performed by a commercial streptavidin/peroxidase (SP) kit
(Zymed, Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instruction. In brief, the tissue microarrays and
breast cancer sections were deparaffinized in xylene, hydrated in
gradient alcohol, and pretreated in a microwave oven for
20 min in citrate buffer (0.01 M, PH 6.0) for antigen retrieval.
T h et i s s u em i c r o a r r a y sa n ds e c t i o n sw e r ei n c u b a t e di n3 %
hydrogen peroxide at room temperature for 10 min to block
endogenous peroxidase activity, and incubated with 10% goat
serum at room temperature for 10 min to reduce nonspecific
immunostaining. Then they were incubated with rabbit
polyclonal antibodies to TSP50 (1:400; Covalab), mouse
monoclonal antibodies to p53 (1:200; DO-7, Santa Cruz
Biotechnology) or mouse monoclonal antibodies to CEA (1:60;
Col-1, Abcam, Cambridge, MA, USA). The primary antibody
reaction was carried out at 4uC overnight. For a negative
control, several breast carcinoma sections were incubated with
PBS (0.01 mol/L, PH 7.4) instead of the primary antibodies.
Sections were incubated for 30 min in respective secondary
antibodies. Antigen–antibody complexes were colored by 3,39-
diaminobenzidine (Zymed, Invitrogen).
Evaluation of immunohistochemical staining
Three pathologists (S.X., J.Z. and Q.W.) evaluated the
immunostaining in a blinded fashion. If there was a discrepancy
in individual evaluations, then all the three pathologists reevalu-
ated the slides together to reach a consensus.
Immunohistochemical stainings of TSP50 and CEA were
evaluated using a semi-quantitative scoring system for both
staining intensity and the percentage of positive epithelial cells
[69]. A score was calculated by multiplying the intensity
(negative scored as 0, mild scored as 1, moderate scored as 2
and strong scored as 3) by percentage of stained cells (0, 0–10%;
1, 10–30%; 2, 30–50%; 3, 50–70%; and 4, 70–100%) [70,71].
Scores of multiplication were graded as follows: 2,0 ;+,1 – 3 ;++,
4–8; +++, 9–12. p53 expression was evaluated according to the
proportion of tumor cells with unequivocal strong nuclear
staining, which was graded as follows: 2 (0–10%); + (11–49%);
++ (50%–74%); +++ ($75%) [28,37]. Additionally, for statistical
analysis, the 2 and 1+ cases were pooled into the low-expression
group, and the 2+ and 3+ cases were pooled into the high-
expression group [72].
Statistical analysis
The relationship between TSP50 expression and type of
colorectal tissues or expression status of p53 or CEA was analyzed
by Kruskal Wallis Test or Spearman’s rho. Chi-square test was
used to analyze the univariate associations of clinicopathological
features with the expression status of TSP50, p53 or CEA. The
statistical significance of each test was set at P,0.05. The ROC
curve was used to calculate and quantify the sensitivity and
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normal colorectal tissues. The PPV, the NPV and Youden index
(sensitivity + specificity - 1) were calculated.
The overall duration of survival was measured from the date of
surgery to the date of death from CRC. Deaths were the outcomes
(events) of interest. Those patients who died from causes other
than CRC, lost contacts after last follow-up, or survived at the end
of the study were considered to be censored. Survival curves were
calculated using the Kaplan-Meier method in each group of
patients with early-stage disease (stages I and II) and advanced-
stage disease (stages III and IV), and differences were analyzed
using the log-rank test. In addition to the primary analysis
described above, Cox regression analysis was performed for
backward stepwise multivariate analysis to find independent
prognostic factors. The statistical significance of each test was
controlled at P,0.05. All analyses were performed using the SPSS
17.0 (SPSS, Chicago, IL, USA).
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